{
  "id": "5e44c33a48dab47f26000020",
  "type": "yesno",
  "question": "Can Enlimomab improve stroke outcomes?",
  "ideal_answer": "No. Anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke and, indeed, may significantly worsen stroke outcome.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
    "http://www.ncbi.nlm.nih.gov/pubmed/12365824",
    "http://www.ncbi.nlm.nih.gov/pubmed/9693236",
    "http://www.ncbi.nlm.nih.gov/pubmed/12038658",
    "http://www.ncbi.nlm.nih.gov/pubmed/9744839",
    "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
    "http://www.ncbi.nlm.nih.gov/pubmed/11692032"
  ],
  "snippets": [
    {
      "text": "Treatment with a murine anti-ICAM-1 antibody (enlimomab) has been investigated in patients with acute ischemic stroke in the Enlimomab Acute Stroke Trial (EAST). Unfortunately, the case fatality rate in this trial was significantly higher in the enlimomab patient group than in the placebo group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12365824",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "en classes of neuroprotective agents have reached phase III efficacy trials but have shown mixed results. They included calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilazad and ebselen, enlimomab, GABA agonist clomethiazole, the sodium channel antagonist fosphenytoin, magnesium, glycine site antagonist GV150526 and piracetam. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12038658",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND PURPOSE: Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ESULTS: At day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004). Fewer patients had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%). The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005). There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nThe authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\n\nAt day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, this treatment failed to show benefit in the Enlimomab Acute Stroke Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9744839",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\nAt day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Unfortunately, the case fatality rate in this trial was significantly higher in the enlimomab patient group than in the placebo group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nDoses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 +/- 10 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9693236",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}